09.11.26 -- Investigator Perspectives On What Matters In Obesity And GLP-1 Studies

How can life sciences companies developing new medicines engage the FDA successfully during a period of rapid changes in agency personnel and policies?  Register for 9-15-26 Crossing The Valley Of Death: New Funding Options For Preclinical And Early-Stage Drug Development for free and learn from an experienced panel of experts about key changes at the FDA, how companies can get the most out of agency interactions, and strategies to lower risks and avoid regulatory surprises.

At-home ophthalmic exams in clinical trials improve patient accessibility, reduce site burden, and maintain data integrity, enabling decentralized research without sacrificing quality or compliance.

Fragmented trial services slow progress. A unified approach to logistics, payments, and data streamlines operations and supports patient-centric trials.

Replace slow international wires with local digital payments, reduce participant friction, and ensure fair, instant reimbursements across the globe.

Retention, body composition, maintenance therapy, amylin combinations, and behavioral support are reshaping obesity trials. Learn how sponsors can reduce dropout risk and strengthen clinical data.

Vendor information is often a hidden source of AP inefficiency. Manual onboarding leads to incomplete records, missing details, and invoice delays, creating friction across purchasing, invoicing, and payments.

Pre-filled syringes offer patient safety and manufacturing benefits, but achieving reliable, efficient filling comes with unique hurdles.

Integrated stable expression strategies speed biologics material generation, improving scalability, consistency, and developability insights while reducing risk and bottlenecks.